PODD and DXCM Related Headlines
Go Back- Barclays Downgrades Insulet Corporation (PODD) to Underweight
- Barclays Downgrades DexCom (DXCM) to Underweight
- Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
- Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
- Stifel resumes coverage on medtech names, sees long-term diabetes devices growth
- Piper Sandler on calls with diabetes clinicians
- Oppenheimer sees stronger growth at Boston Scientific
- Medical device maker stocks falls after proposed Medicare payment cuts
- Piper Sandler's Key MedTech Takeaways From ADA 2025
- Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
